Embecta Corp. EMBC
6.50 USD +0.07 (+1.01%)
Nov 11, 2026, 3:56 PM EST
6.35 Day range 6.60
2.77 52-week range 14.91
- YTD
- -45.33%
- 1 year
- -54.32%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
benzinga.com Embecta Raises FY2026 Adj EPS Guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 Est; Affirms FY2026 Sales Guidance of $1.015B-$1.035B vs $1.021B Est Embecta (NASDAQ:EMBC) raises FY2026 Adj EPS guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 analyst estimate. Affirms FY2026 sales outlook from $1.015 billion-$1.035 billion to $1.015…
benzinga.com B of A Securities Maintains Underperform on Embecta, Lowers Price Target to $3 B of A Securities analyst Travis Steed maintains Embecta (NASDAQ:EMBC) with a Underperform and lowers the price target from $11 to $3.
benzinga.com Mizuho Maintains Neutral on Embecta, Lowers Price Target to $5 Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $12 to $5.
benzinga.com Crude Oil Down 4%; PayPal Shares Fall After Q1 Results US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Embecta Lowers FY2026 Adj EPS Guidance from $2.80-$3.00 to $1.55-$1.75 vs $2.81 Est; Lowers FY2026 Sales Guidance from $1.071B-$1.093B to $1.015B-$1.035B vs $1.071B Est Embecta (NASDAQ:EMBC) lowers FY2026 Adj EPS guidance from $2.80-$3.00 to $1.55-$1.75 vs $2.81 analyst estimate. Lowers FY2026 sales outlook from $1.071 billion-$1.093 billion to $1.015 billion-$1.035…- benzinga.com Embecta Q2 Adj. EPS $0.27 Misses $0.42 Estimate, Sales $221.800M Miss $235.567M Estimate Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.42 by 35.71 percent. This is a 61.43 percent decrease over earnings of $0.70 per…
benzinga.com Under the Radar: Why "Fixing" a Great Strategy Usually Breaks It - benzinga.com Embecta Agrees To Acquire Owen Mumford For £150M Embecta Corp. ("Embecta") (NASDAQ:EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited ("Owen…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Embecta Affirms FY2026 Adj EPS Guidance of $2.80-$3.00 vs $2.91 Est; Affirms FY2026 Sales Guidance of $1.071B-$1.093B vs $1.080B Est Embecta (NASDAQ:EMBC) affirms FY2026 Adj EPS guidance from $2.80-$3.00 to $2.80-$3.00 vs $2.91 analyst estimate. Affirms FY2026 sales outlook from $1.071 billion-$1.093 billion to $1.071…
benzinga.com Embecta Q1 Earnings Summary & Key Takeaways 
benzinga.com Embecta Q1 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $261.200M Beat $258.043M Estimate Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. This is a 9.23 percent increase over earnings of $0.65 per…- benzinga.com Earnings Scheduled For February 5, 2026
benzinga.com A Look Into Embecta Inc's Price Over Earnings 
benzinga.com Embecta Sees FY2026 Adj EPS $2.80-$3.00 vs $2.89 Est; Sees Sales $1.071B-$1.093B vs $1.082B Est Preliminary Fiscal Year 2026 Financial Guidance:For fiscal year 2026, the Company expects:Dollars in millions, except percentages and per share data Reported Revenues$1,071 - $1,093Reported Revenue…- benzinga.com Earnings Scheduled For November 25, 2025
benzinga.com Embecta's Earnings: A Preview - benzinga.com Embecta Devdatt Kurdikar To Become Chairman Of Board Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J.…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Embecta Raises FY2025 Adj EPS Guidance from $2.70-$2.90 to $2.90-$2.95 vs $2.82 Est; Narrows FY2025 Sales Guidance from $1.073B-$1.090B to $1.078B-$1.085B vs $1.083B Est Fiscal Year 2025 Updated Financial Guidance:For fiscal year 2025, the Company now expects:Dollars in millions, except percentages and per share dataCurrentPrevious(1)Reported Revenues$1,078 -…
- benzinga.com Earnings Scheduled For August 8, 2025
benzinga.com An Overview of Embecta's Earnings - benzinga.com Mizuho Maintains Neutral on Embecta, Lowers Price Target to $12 Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $13 to $12.
- benzinga.com Mizuho Maintains Neutral on Embecta, Lowers Price Target to $13 Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $15 to $13.
benzinga.com Embecta Reaffirms 2025 Outlook With Up to $1.09B Revenue, Unveils Long-Term Plan to Cut $500M Debt Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase…
benzinga.com Why Is Embecta Stock Falling On Friday? Embecta reaffirms earnings outlook, trims revenue forecast, and boosts cash flow as restructuring and cost controls offset tariff and FX headwinds.- benzinga.com Embecta Affirms FY2025 Adj EPS Guidance of $2.70-$2.90 vs $2.80 Est; Lowers FY2025 Sales Guidance of $1.07B-$1.09B vs $1.09B Est Embecta (NASDAQ:EMBC) affirms FY2025 Adj EPS guidance from $2.70-$2.90 to $2.70-$2.90 vs $2.80 analyst estimate. Lowers FY2025 sales outlook from $1.07 billion-$1.09 billion to $1.07 billion-$1.09…
- benzinga.com Embecta Q2 Adj. EPS $0.70 Beats $0.53 Estimate, Sales $259.00M Beat $253.94M Estimate Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.53 by 32.08 percent. This is a 4.48 percent increase over earnings of $0.67 per…
- benzinga.com Earnings Scheduled For May 9, 2025
- benzinga.com A Peek at Embecta's Future Earnings
- benzinga.com Mizuho Initiates Coverage On Embecta with Neutral Rating, Announces Price Target of $15 Mizuho analyst Anthony Petrone initiates coverage on Embecta (NASDAQ:EMBC) with a Neutral rating and announces Price Target of $15.
benzinga.com Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.- benzinga.com Embecta Affirms FY2025 Adj EPS Guidance from $2.70-2.90 to $2.70-2.90 vs $2.81 Est; Lowers FY2025 Sales Guidance from $1.09B-1.11B to $1.07B-1.09B vs $1.10B Est Embecta (NASDAQ:EMBC) affirms FY2025 Adj EPS guidance from $2.70-2.90 to $2.70-2.90 vs $2.81 analyst estimate. Lowers FY2025 sales outlook from $1.09 billion-1.11 billion to $1.07 billion-1.09…
benzinga.com Embecta Q1 2025 Adj. EPS $0.65 Beats $0.44 Estimate, Sales $261.900M Beat $254.617M Estimate Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.44 by 47.73 percent. This is a 6.56 percent increase over earnings of $0.61 per…- benzinga.com Earnings Scheduled For February 6, 2025
benzinga.com Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to…
benzinga.com Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
- benzinga.com This Dick's Sporting Goods Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
- benzinga.com BTIG Upgrades Embecta to Buy, Announces $26 Price Target BTIG analyst Marie Thibault upgrades Embecta (NASDAQ:EMBC) from Neutral to Buy and announces $26 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views
- benzinga.com Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring plans with cost-saving measures.
- benzinga.com Nasdaq Rises 100 Points; Abercrombie & Fitch Shares Fall After Q3 Results
- benzinga.com J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday